$CRGX News
Last published 1y ago
- 1y agoCRGXCARGO Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $4.379 in Cash per Share Plus a Contingent Value RightGlobeNewswireSAN CARLOS, Calif., July 08, 2025 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. ("CARGO" or the "Company") (NASDAQ:CRGX), a biotechnology company that has focused on developing CAR T-cell therapies, today announced that
- 1y agoCRGXCARGO Therapeutics Provides Corporate UpdateGlobeNewswire- Development of CRG-023 and allogeneic platform suspended; further reduction in force (RIF) of approximately 90% to preserve cash and maximize shareholder value - - CARGO had cash, cash equivalents and marketable
- 1y agoCRGXCARGO Therapeutics to Discontinue FIRCE-1 Phase 2 Study of Firi-cel; Advances Remaining Programs While Evaluating Strategic OptionsGlobeNewswireCARGO elects to discontinue FIRCE-1, a Phase 2 clinical study of firicabtagene autoleucel (firi-cel)1; Company believes results do not support a competitive benefit-risk profile for patients.CARGO to implement a
- 1y agoCRGXCARGO Therapeutics Provides Corporate Update and Anticipated Milestones for 2025GlobeNewswire- 71 patients dosed in the potentially pivotal Phase 2 clinical study of firicabtagene autoleucel (firi-cel); Interim analysis results expected to be reported in 1H'25 - - IND application for CRG-023, CARGO's
- 1y agoONCYCRGXIMRXRNXT+1How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment OptionsPR NewswireUSA News Group News Commentary – Recent advancements in cancer treatment continue to underscore the transformative potential of innovative therapies...
- 1y agoONCYCRGXIMRXRNXT+1How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment OptionsPR NewswireUSA News Group News Commentary – Recent advancements in cancer treatment continue to underscore the transformative potential of innovative therapies...
- 1y agoCGEMCRGXDCTHELVN+8Clear Street Launches Healthcare & Biotechnology Equity ResearchBusiness WireComprehensive Biotechnology sector market analysis and investment insights complement recently launched Disruptive Technology and Energy Transition franchises Clear Street, ("Clear Street", "the Company") a
- 1y agoCRGXCARGO Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare ConferenceGlobeNewswireSAN CARLOS, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ:CRGX), a clinical-stage biotechnology company positioned to advance next-generation, potentially curative cell therapies for cancer
- 1y agoCRGXCARGO Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswire- 57 patients dosed in the potentially pivotal Phase 2 clinical study, FIRCE-1 of firicabtagene autoleucel (firi-cel); on track for interim analysis in 1H25 - - CRG-023 pre-clinical data to be presented at ASH 2024; IND
- 2y agoCRGXCARGO Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireSAN CARLOS, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ:CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer
- 2y agoCRGXCARGO Therapeutics Announces ASH 2024 Abstract on CRG-023, a Tri-specific CAR T, Highlighting Innovative Construct Design and Durable Anti-B-Cell Lymphoma ActivityGlobeNewswire- CRG-023 is a CD19-, CD20-, CD22-targeting tri-specific CAR T product candidate designed with the goal of providing more patients with a broad range of B-cell malignancies with durable responses by addressing several
- 2y agoCRGXCARGO Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswire- All sites activated with 38 patients dosed in the potentially pivotal Phase 2 clinical study, FIRCE-1 of firicabtagene autoleucel (firi-cel) - - Completed $110 million private placement equity financing, extending
- 2y agoCRGXCARGO Therapeutics Announces Phase 1 Clinical Study of Firi-cel CAR T-Cell Therapy Published in The LancetGlobeNewswireOngoing Phase 1 study informed dose selection for CARGO's currently enrolling, potentially pivotal Phase 2 clinical study, FIRCE-1 of firicabtagene autoleucel (firi-cel)1, in patients with relapsed or refractory (R/R)
- 2y agoCRGXCARGO Therapeutics Adds Experienced Biopharma Executive to Board of Directors with the Appointment of Jane Pritchett Henderson as Independent DirectorGlobeNewswire– Appointment adds strategic finance and broad operating experience to Board as Company advances potentially pivotal Phase 2 clinical study for CAR T-cell therapy candidate, firicabtagene autoleucel (firi-cel) – SAN
- 2y agoCRGXCARGO Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireSAN CARLOS, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ:CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer
- 2y agoCRGXCARGO Therapeutics Announces $110.0 Million Private Placement Equity FinancingGlobeNewswire– Financing includes participation from new and existing investors – – Supports BLA preparation for potentially pivotal Phase 2 study, FIRCE-1 of firicabtagene autoleucel (firi-cel) (CRG-022) and IND-enabling studies
- 2y agoCRGXCARGO Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswire- 26 sites activated and over 20 patients dosed in the potentially pivotal Phase 2 clinical study, FIRCE-1 of firicabtagene autoleucel (firi-cel) (CRG-022); Currently on-track for interim results expected in 1H25 - -
- 2y agoCRGXCARGO Therapeutics Names Kapil Dhingra, M.B.B.S., to Board of DirectorsGlobeNewswireSAN MATEO, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ:CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer
- 2y agoCRGXCARGO Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateGlobeNewswire– Potentially pivotal Phase 2 clinical study FIRCE-1 of firicabtagene autoleucel (CRG-022) is rapidly recruiting with 20 sites open to date; interim results expected 1H 2025 – SAN MATEO, Calif., March 21, 2024
- 2y agoCRGXCARGO Therapeutics to Participate in the 44th Annual Cowen Healthcare ConferenceGlobeNewswireSAN MATEO, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ:CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer
- 2y agoCRGXCARGO Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare ConferenceGlobeNewswireSAN MATEO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ:CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer
- 2y agoCRGXCARGO Therapeutics Reports Business Updates and Third Quarter 2023 ResultsGlobeNewswireSAN MATEO, Calif., Dec. 13, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ:CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer